Disrupting KAT8 Liquid-Liquid Phase Separation with Hybrid Vesicle-Liposome Platform for Enhanced PD-L1 Blockade Treatment - PubMed
10 hours ago
- #PD-L1 blockade
- #hybrid vesicle-liposome delivery
- #KAT8 LLPS disruption
- KAT8 nucleates liquid-liquid phase separation (LLPS) condensates that drive sustained PD-L1 transcription and immune resistance.
- PD-1-HVL-siKAT8 is a hybrid vesicle-liposome platform for siRNA delivery, combining tumor targeting via PD-1 with cytosolic siRNA release.
- The platform disrupts KAT8-mediated LLPS, suppressing PD-L1 expression and enhancing immune responses in hepatocellular carcinoma models.
- Treatment with PD-1-HVL-siKAT8 inhibits tumor growth, prevents recurrence, extends survival, and shows negligible toxicity in preclinical models.